GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Valuation Rank

Shanghai Henlius Biotech (HKSE:02696) Valuation Rank


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Shanghai Henlius Biotech Valuation Rank Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Henlius Biotech (HKSE:02696) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Valuation Rank
Comparable Companies
HKSE:00775 HKSE:02157 HKSE:06855 HKSE:02480 HKSE:02105 HKSE:02487 HKSE:06955 HKSE:02171 HKSE:02315 HKSE:02179 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
No. 1801 Hongmei Road, 9th Floor, Innov Tower (Capitaland Building), Xuhui District, Shanghai, CHN, 200233
Website
https://www.henlius.com
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Executives
Qatar Investment Authority 2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited 2101 Beneficial owner
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Liu Scott Shi-kau 2201 Interest of corporation controlled by you
Jiang Wei-dong 2201 Interest of corporation controlled by you
Henlius Biopharmaceuticals, Inc. 2101 Beneficial owner